

Edgar Filing: BALCHEM CORP - Form 10-Q

BALCHEM CORP
Form 10-Q
November 06, 2009

FORM 10-Q

SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

(Mark One) Quarterly Report Pursuant to Section 13 or 15(d) of
X the Securities Exchange Act of 1934

For The Quarterly Period Ended September 30, 2009

or

Transition Report Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934

For the transition period from _____ to _____

Commission File Number 1-13648

BALCHEM CORPORATION
(Exact name of registrant as specified in its charter)

Maryland 13-2578432

(State or other jurisdiction of (I.R.S. Employer Identification Number)
incorporation or organization)

P.O. Box 600 New Hampton, New York 10958

(Address of principal executive offices) (Zip Code)

845-326-5600

Registrant's telephone number, including area code:

Indicate by a check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to
filing requirements for the past 90 days.

Yes No

Indicate by check mark whether the registrant has submitted electronically and
posted on its corporate Web site, if any, every Interactive Data File required
to be submitted and posted pursuant to Rule 405 of Regulation S-T (ss.232.405 of
this chapter) during the preceding 12 months (or for such shorter period that
the registrant was required to submit and post such files).

Yes No

Indicate by check mark whether the Registrant is a large accelerated filer, an
accelerated filer, a non-accelerated filer, or a smaller reporting company. See
the definitions of "large accelerated filer," "accelerated filer" and "smaller
reporting company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer Accelerated filer
Non-accelerated filer Smaller reporting company

Edgar Filing: BALCHEM CORP - Form 10-Q

Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

As of November 1, 2009 the registrant had 18,653,765 shares of its Common Stock, \$.06 2/3 par value, outstanding.

Part 1 - Financial Information
Item 1. Financial Statements

BALCHEM CORPORATION
Condensed Consolidated Balance Sheets
(Dollars in thousands, except per share data)

	Assets -----	September 30, 2009 (unaudited) -----
Current assets:		
Cash and cash equivalents		\$ 38,778
Accounts receivable, net		26,351
Inventories		14,679
Prepaid expenses		1,104
Prepaid income taxes		451
Deferred income taxes		855
Other current assets		442

Total current assets		82,660
Property, plant and equipment, net		41,626
Goodwill		26,658
Intangible assets with finite lives, net		27,288
Other assets		61

Total assets		\$178,293 =====
Liabilities and Stockholders' Equity -----		
Current liabilities:		
Trade accounts payable		\$ 7,850
Accrued expenses		7,625
Accrued compensation and other benefits		4,040
Dividends payable		--
Income tax payable		2,920
Current portion of long-term debt		7,295
Revolver borrowings		--

Total current liabilities		29,730
Long-term debt		--
Deferred income taxes		4,837
Other long-term obligations		1,752

Total liabilities		36,319

Edgar Filing: BALCHEM CORP - Form 10-Q

Commitments and contingencies (note 12)

Stockholders' equity:

Common stock, \$.0667 par value. Authorized 25,000,000 shares; 18,652,077 shares issued and outstanding at September 30, 2009 and 18,249,347 shares issued and outstanding at December 31, 2008	850
Preferred stock, \$25 par value. Authorized 2,000,000 shares; none issued and outstanding	--
Additional paid-in capital	26,150
Retained earnings	114,701
Accumulated other comprehensive income (loss)	273
Total stockholders' equity	141,974
Total liabilities and stockholders' equity	\$178,293

See accompanying notes to condensed consolidated financial statements.

2

BALCHEM CORPORATION
Condensed Consolidated Statements of Earnings
(Dollars in thousands, except per share data)
(unaudited)

	Three Months Ended September 30,		Nine Months September
	2009	2008	2009
	-----	-----	-----
Net sales	\$ 54,292	\$ 58,235	\$ 160,254
Cost of sales	37,893	45,523	110,253
	-----	-----	-----
Gross margin	16,399	12,712	50,001
Operating expenses:			
Selling expenses	3,393	3,068	10,873
Research and development expenses	740	681	2,428
General and administrative expenses	1,963	1,737	6,802
	-----	-----	-----
	6,096	5,486	20,103
	-----	-----	-----
Earnings from operations	10,303	7,226	29,898
Other expenses (income):			
Interest income	(8)	(17)	(38)
Interest expense	27	222	142

Edgar Filing: BALCHEM CORP - Form 10-Q

Other, net	(39)	85	2
	-----	-----	-----
Earnings before income tax expense	10,323	6,936	29,792
Income tax expense	3,471	2,143	9,973
	-----	-----	-----
Net earnings	\$ 6,852	\$ 4,793	\$ 19,819
	=====	=====	=====
Net earnings per common share - basic	\$ 0.37	\$ 0.27	\$ 1.09
	=====	=====	=====
Net earnings per common share - diluted	\$ 0.36	\$ 0.25	\$ 1.03
	=====	=====	=====

See accompanying notes to condensed consolidated financial statements.

3

BALCHEM CORPORATION
Condensed Consolidated Statements of Cash Flows
(Dollars in thousands)
(unaudited)

	Nine Months End September 30 2009	-----
Cash flows from operating activities:		
Net earnings	\$ 19,819	\$
Adjustments to reconcile net earnings to net cash provided by operating activities:		
Depreciation and amortization	6,082	
Reserve for doubtful accounts	464	
Shares issued under employee benefit plans	345	
Deferred income taxes	(1,379)	
Foreign currency transaction loss	34	
Stock compensation expense	2,252	
Changes in assets and liabilities:		
Accounts receivable	3,658	
Inventories	1,998	
Prepaid expenses and other current assets	2,795	
Income taxes	383	
Accounts payable and accrued expenses	2,492	
Other	122	

Net cash provided by operating activities	39,065	-----
Cash flows from investing activities:		
Capital expenditures	(2,141)	
Proceeds from sale of property, plant and equipment	4	

Edgar Filing: BALCHEM CORP - Form 10-Q

Intangible assets acquired	(85)
Acquisition of assets	--

Net cash used in investing activities	(2,222)

Cash flows from financing activities:	
Revolver borrowings	701
Revolver repayments	(2,657)
Principal payments on long-term debt	(2,448)
Proceeds from stock options exercised	2,712
Excess tax benefits from stock compensation	2,058
Dividends paid	(2,008)

Net cash used in financing activities	(1,642)

Effect of exchange rate changes on cash	155

Increase in cash and cash equivalents	35,356
Cash and cash equivalents beginning of period	3,422

Cash and cash equivalents end of period	\$ 38,778
	=====

See accompanying notes to condensed consolidated financial statements.

4

BALCHEM CORPORATION
Condensed Consolidated Statements of Comprehensive Income
(Dollars in thousands)
(unaudited)

	Three Months Ended		Nine Months Ended	
	September 30,		September 30,	
	2009	2008	2009	2008
	-----	-----	-----	-----
Net earnings	\$6,852	\$ 4,793	19,819	\$ 14,1
Other comprehensive income, net of tax:				
Other	163	(172)	281	(1
	-----	-----	-----	-----
Comprehensive income	\$7,015	\$ 4,621	20,100	\$ 14,0
	=====	=====	=====	=====

See accompanying notes to condensed consolidated financial statements.

5

Edgar Filing: BALCHEM CORP - Form 10-Q

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(All dollar amounts in thousands, except per share data)

NOTE 1 - CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

The condensed consolidated financial statements presented herein have been prepared by the Company in accordance with the accounting policies described in its December 31, 2008 consolidated financial statements, and should be read in conjunction with the consolidated financial statements and notes, which appear in the Annual Report on Form 10-K for the year ended December 31, 2008. References in this report to the "Company" mean either Balchem Corporation or Balchem Corporation and its subsidiaries, including BCP Ingredients, Inc., Balchem Minerals Corporation, and Balchem B.V., on a consolidated basis, as the context requires.

In the opinion of management, the unaudited condensed consolidated financial statements furnished in this Form 10-Q include all adjustments necessary for a fair presentation of the financial position, results of operations and cash flows for the interim periods presented. All such adjustments are of a normal recurring nature. The condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles ("U.S. GAAP" or "GAAP") governing interim financial statements and the instructions to Form 10-Q and Article 10 of Regulation S-X under the Securities Exchange Act of 1934 and therefore do not include some information and notes necessary to conform to annual reporting requirements. Certain prior year amounts have been reclassified to conform to current year presentation. The results of operations for the nine months ended September 30, 2009 are not necessarily indicative of the operating results expected for the full year or any interim period.

The Company follows accounting standards set by the Financial Accounting Standards Board, commonly referred to as the "FASB." The FASB sets U.S. generally accepted accounting principles that the Company follows to ensure the Company consistently reports its financial condition, results of operations, and cash flows. References to GAAP issued by the FASB in these footnotes are to the FASB Accounting Standards Codification, sometimes referred to as the "Codification" or "ASC". The FASB finalized the Codification effective for periods ending on or after September 15, 2009. FASB will no longer issue new standards in the form of Statements, FASB Staff Positions, or Emerging Issues Task Force Abstracts. For further discussion of the Codification see Note 13 and "FASB Codification Discussion" in Management's Discussion and Analysis of Financial Condition and Results of Operations ("MD&A") elsewhere in this report.

NOTE 2 - STOCKHOLDERS' EQUITY

STOCK-BASED COMPENSATION

The Company records stock-based compensation in accordance with the provisions of ASC 718, "Compensation-Stock Compensation" (incorporating former Statement of Financial Accounting Standards ("SFAS") No. 123 (revised 2004), "Share Based Payment"). The Company's results for the three and nine months ended September 30, 2009 and 2008 reflected the following stock-based compensation cost, and such

compensation cost had the following effects on net earnings and basic and

Edgar Filing: BALCHEM CORP - Form 10-Q

diluted earnings per share:

	Three Months Ended September 30, 2009	Three Months Ended September 30, 2008
Cost of sales	\$ 88	\$ 66
Operating expenses	659	485
Net earnings	(522)	(372)
Basic earnings per common share	(0.03)	(0.02)
Diluted earnings per common share	\$ (0.03)	\$ (0.02)

	Nine Months Ended September 30, 2009	Nine Months Ended September 30, 2008
Cost of sales	\$ 266	\$ 198
Operating expenses	1,986	1,597
Net earnings	(1,445)	(1,194)
Basic earnings per common share	(0.08)	(0.07)
Diluted earnings per common share	\$ (0.08)	\$ (0.06)

As required by ASC 718, the Company has made an estimate of expected forfeitures based on its historical experience and is recognizing compensation cost only for those stock-based compensation awards expected to vest.

The Company's stock incentive plans allow for the granting of restricted stock awards and options to purchase common stock. Both incentive stock options and nonqualified stock options can be awarded under the plans. No option will be exercisable for longer than ten years after the date of grant. The Company has approved and reserved a number of shares to be issued upon exercise of the outstanding options that is adequate to cover all exercises. As of September 30, 2009, the plans had 3,666,450 shares available for future awards. Compensation expense for stock options and restricted stock awards is recognized on a straight-line basis over the vesting period, generally three years for stock options, four years for employee restricted stock awards, and four to seven years for non-employee director restricted stock awards. Certain awards provide for accelerated vesting if there is a change in control (as defined in the plans) or other qualifying events.

Option activity for the nine months ended September 30, 2009 and 2008 is summarized below:

Edgar Filing: BALCHEM CORP - Form 10-Q

For the Nine months ended September 30, 2009	Shares (000s)	Weighted Average Exercise Price	Aggregate Intrinsic Value (\$000s)
Outstanding as of December 31, 2008	2,396	\$ 13.82	\$ 26,873
Granted	1	24.86	
Exercised	(389)	6.98	
Forfeited	(10)	21.10	
Outstanding as of September 30, 2009	1,998	\$ 15.11	\$ 22,361
Exercisable as of September 30, 2009	1,369	\$ 11.78	\$ 19,873

For the Nine months ended September 30, 2008	Shares (000s)	Weighted Average Exercise Price	Aggregate Intrinsic Value (\$000s)
Outstanding as of December 31, 2007	1,944	\$ 10.66	\$ 22,786
Granted	308	20.42	
Exercised	(127)	7.91	
Outstanding as of September 30, 2008	2,125	\$ 12.23	\$ 30,684
Exercisable as of September 30, 2008	1,578	\$ 9.80	\$ 26,623

ASC 718 requires companies to measure the cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award. The fair value of each option grant is estimated on the date of the grant using the Black-Scholes option-pricing model with the following weighted average assumptions: dividend yields of 0.5% and 0.5%; expected volatilities of 50% and 41%; risk-free interest rates of 1.8% and 2.7%; and expected lives of 3.3 and 3.4, in each case for the nine months ended September 30, 2009 and 2008, respectively.

The Company used a projected expected life for each award granted based on historical experience of employees' exercise behavior. Expected volatility is based on the Company's historical volatility levels. Dividend yields are based on the Company's historical dividend yields. Risk-free interest rates are based on the implied yields currently available on U.S. Treasury zero coupon issues with a remaining term equal to the expected life.

Edgar Filing: BALCHEM CORP - Form 10-Q

Other information pertaining to option activity during the three and nine months ended September 30, 2009 and 2008 was as follows:

8

	Three Months Ended September 30, 2009		Nine Months September 2009	
Weighted-average fair value of options granted	\$	N/A	\$	8.31
Total intrinsic value of stock options exercised (\$000s)	\$	2,010	\$	294
			\$	8.88
			\$	6,845

Non-vested restricted stock activity for the nine months ended September 30, 2009 and 2008 is summarized below:

Nine months ended September 30, 2009	Shares (000s)	Weighted Average Grant Date Fair Value
Non-vested balance as of December 31, 2008	232	\$ 2
Non-vested balance as of September 30, 2009	232	\$ 2

Nine months ended September 30, 2008	Shares (000s)	Weighted Average Grant Date Fair Value
Non-vested balance as of December 31, 2007	118	\$ 16
Granted	73	20
Vested	(18)	17
Non-vested balance as of September 30, 2008	173	\$ 18

As of September 30, 2009 and 2008, there was \$5,188 and \$4,182, respectively, of total unrecognized compensation cost related to non-vested share-based compensation arrangements granted under the plans. As of September 30, 2009, the unrecognized compensation cost is expected to be recognized over a weighted-average period of 2 years. The Company estimates that share-based compensation expense for the year ended December 31, 2009 will be approximately \$3,000.

Edgar Filing: BALCHEM CORP - Form 10-Q

REPURCHASE OF COMMON STOCK

The Company has a stock repurchase program that was approved by the board of directors. The total authorization under this program is 2,508,692 shares. Since the inception of the program, a total of 1,307,867 shares have been purchased, none of which remained in treasury at September 30, 2009 or 2008. During the nine months ended September 30, 2009, no additional shares have been purchased. The Company intends to acquire shares from time to time at prevailing market prices if and to the extent it deems it advisable to do so based on its assessment of corporate cash flow, market conditions and other factors.

NOTE 3 - INVENTORIES

Inventories at September 30, 2009 and December 31, 2008 consisted of the following:

9

	September 30, 2009	December 31, 2008
Raw materials	\$ 5,027	\$ 5,931
Work in progress	743	540
Finished goods	8,909	10,147
Total inventories	\$14,679	\$16,618

NOTE 4 - PROPERTY, PLANT AND EQUIPMENT

Property, plant and equipment at September 30, 2009 and December 31, 2008 are summarized as follows:

	September 30, 2009	December 31, 2008
Land	\$ 2,138	\$ 2,088
Building	15,638	15,426
Equipment	53,062	50,719
Construction in progress	2,559	2,654
	73,397	70,887
Less: accumulated depreciation	31,771	28,374
Net property, plant and equipment	\$41,626	\$42,513

NOTE 5 - INTANGIBLE ASSETS

The Company had goodwill in the amount of \$26,658 as of September 30, 2009 and December 31, 2008 subject to the provisions of ASC 350, "Intangibles-Goodwill and Other" (incorporating former SFAS No. 141, "Business Combinations"; and SFAS

Edgar Filing: BALCHEM CORP - Form 10-Q

No. 142, "Goodwill and Other Intangible Assets").

As of September 30, 2009 and December 31, 2008, the Company had identifiable intangible assets with finite lives with a gross carrying value of approximately \$37,465 and \$37,431, respectively, less accumulated amortization of \$10,177 and \$7,438, respectively.

Identifiable intangible assets with finite lives at September 30, 2009 and December 31, 2008 are summarized as follows:

	Amortization Period (in years)	Gross Carrying Amount at 9/30/09	Accumulated Amortization at 9/30/09	Gross Carrying Amount at 12/31/08
Customer lists	10	\$34,150	\$ 9,159	\$ 34,150
Regulatory re-registration costs	10	85	9	85
Patents & trade secrets	15-17	1,683	480	1,673
Trademarks & trade names	17	911	238	904
Other	5-10	636	291	619
		\$37,465	\$ 10,177	\$37,431

Amortization of identifiable intangible assets was approximately \$2,739 and \$2,729 for the nine months ended September 30, 2009 and 2008, respectively. Assuming no change

10

in the gross carrying value of identifiable intangible assets, the estimated amortization expense for the remainder of 2009 is \$911 and approximately \$3,600 per annum for 2010 through 2014. At September 30, 2009, there were no identifiable intangible assets with indefinite useful lives as defined by ASC 350. Identifiable intangible assets are reflected in "Intangible assets with finite lives, net" in the Company's condensed consolidated balance sheets. There were no changes to the useful lives of intangible assets subject to amortization during the nine months ended September 30, 2009.

NOTE 6 - NET EARNINGS PER SHARE

The following presents a reconciliation of the net earnings and shares used in calculating basic and diluted net earnings per share:

	Net Earnings (Numerator)	Number of Shares (Denominator)
Three months ended September 30, 2009		

Basic EPS - Net earnings and weighted

Edgar Filing: BALCHEM CORP - Form 10-Q

average common shares outstanding	\$ 6,852	18,385,081
Effect of dilutive securities - stock options and restricted stock		917,835 -----
Diluted EPS - Net earnings and weighted average common shares outstanding and effect of stock options and restricted stock	\$ 6,852	19,302,916

	Net Earnings (Numerator)	Number of Shares (Denominator)
Three months ended September 30, 2008		
Basic EPS - Net earnings and weighted average common shares outstanding	\$ 4,793	18,007,236
Effect of dilutive securities - stock options and restricted stock		1,123,319 -----
Diluted EPS - Net earnings and weighted average common shares outstanding and effect of stock options and restricted stock	\$ 4,793	19,130,555

11

	Net Earnings (Numerator)	Number of Shares (Denominator)
Nine months ended September 30, 2009		
Basic EPS - Net earnings and weighted average common shares outstanding	\$ 19,819	18,226,296
Effect of dilutive securities - stock options and restricted stock		945,874 -----
Diluted EPS - Net earnings and weighted average common shares outstanding and effect of stock options and restricted stock	\$ 19,819	19,172,170

Edgar Filing: BALCHEM CORP - Form 10-Q

Nine months ended September 30, 2008	Net Earnings (Numerator)	Number of Shares (Denominator)
Basic EPS - Net earnings and weighted average common shares outstanding	\$ 14,158	17,950,082
Effect of dilutive securities - stock options and restricted stock		1,037,283
Diluted EPS - Net earnings and weighted average common shares outstanding and effect of stock options and restricted stock	\$ 14,158	18,987,365

The Company had stock options covering 274,800 and -0- shares at September 30, 2009 and 2008, respectively, that could potentially dilute basic earnings per share in future periods that were not included in diluted earnings per share because their effect on the period presented was anti-dilutive.

NOTE 7 - INCOME TAXES

The Company accounts for uncertainty in income taxes in accordance with ASC 740-10 (incorporating former FASB Interpretation No. 48, "Accounting for Uncertainty in Income Taxes"). ASC 740-10 clarifies whether or not to recognize assets or liabilities for tax positions taken that may be challenged by a tax authority. Upon adoption of ASC 740-10, the Company recognized approximately a \$291 decrease in its retained earnings balance. The charge before federal tax benefits was \$411. The Company includes interest expense or income as well as potential penalties on unrecognized tax positions as a component of income tax expense in the consolidated statements of earnings. The total amount of accrued interest and penalties related to uncertain tax positions at September 30, 2009 was approximately \$150 and is included in other long-term obligations. All of the unrecognized tax benefits, if recognized in future periods, would impact the Company's effective tax rate. The Company files income tax returns in the U.S. and in various states and foreign countries. As of September 30, 2009, in the major jurisdictions where the Company operates, it is generally no longer subject to income tax examinations by tax authorities for years before 2006. There was not a significant change in the liabilities for unrecognized tax benefits during the nine months ended September 30, 2009.

12

NOTE 8 - SEGMENT INFORMATION

The Company's reportable segments are strategic businesses that offer products and services to different markets. Presently, the Company has three segments: Specialty Products; Food, Pharma & Nutrition; and Animal Nutrition & Health.

Business Segment Net Sales:

Three Months Ended

Nine Months Ended

Edgar Filing: BALCHEM CORP - Form 10-Q

	September 30,		September 30,	
	2009	2008	2009	2008
Specialty Products	\$ 9,119	\$ 9,298	\$ 27,006	\$ 26,564
Food, Pharma & Nutrition	8,639	9,362	26,034	28,122
Animal Nutrition & Health	36,534	39,575	107,214	123,311
Total	\$54,292	\$58,235	\$160,254	\$177,997

Business Segment Earnings Before Income Taxes:

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2009	2008	2009	2008
Specialty Products	\$ 3,686	\$ 3,391	\$ 10,822	\$ 8,709
Food, Pharma & Nutrition	1,342	1,565	3,584	4,763
Animal Nutrition & Health	5,275	2,270	15,492	8,398
Interest and other income (expense)	20	(290)	(106)	(742)
Total	\$10,323	\$ 6,936	\$ 29,792	\$ 21,128

The following table summarizes domestic (U.S.) and foreign sales for the three and nine months ended September 30, 2009 and September 30, 2008:

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2009	2008	2009	2008
Domestic	\$35,711	\$37,005	\$107,711	\$107,803
Foreign	18,581	21,230	52,543	70,194
Total	\$54,292	\$58,235	\$160,254	\$177,997

NOTE 9 - SUPPLEMENTAL CASH FLOW INFORMATION

Cash paid during the nine months ended September 30, 2009 and 2008 for income taxes and interest is as follows:

	Nine months ended September 30,	
	2009	2008
Income taxes	\$ 8,969	\$ 7,084
Interest	\$ 189	\$ 757

NOTE 10 - LONG-TERM DEBT AND CREDIT AGREEMENTS

On April 30, 2007, the Company, and its principal bank entered into a Loan Agreement (the "European Loan Agreement") providing for an unsecured term loan of (euro)7,500, translated to \$10,943 as of September 30, 2009 (the "European Term Loan"), the proceeds of which were used to fund the 2007 Akzo Nobel Acquisition (described in Note 5 of the Company's Form 10-K as of December 31, 2008) and initial working capital requirements. The European Term Loan is payable in equal monthly installments of principal, each equal to 1/84th of the principal of the European Term Loan, together with accrued interest, with remaining principal and interest payable at maturity. The European Term Loan has a maturity date of May 1, 2010 and is subject to a monthly interest rate equal to EURIBOR plus 1%. At September 30, 2009, this interest rate was 1.49%. At September 30, 2009, the European Term Loan had an outstanding balance of (euro)5,000, translated to \$7,295. The European Loan Agreement also provides for a short-term revolving credit facility of (euro)3,000, translated to \$4,377 as of September 30, 2009 (the "European Revolving Facility"). The European Revolving Facility has been renewed for a period of one year as of May 1, 2009. The current European Revolving Facility is subject to an amended monthly interest rate equal to EURIBOR plus 1.45%, and accrued interest is payable monthly. No amounts are outstanding on the European Revolving Facility as of the date hereof. Management believes that such facility will be renewed in the normal course of business.

On March 16, 2007, the Company and its principal bank entered into a Loan Agreement (the "Loan Agreement") providing for an unsecured term loan of \$29,000 (the "Term Loan"), the proceeds of which were used to fund the 2007 Chinook Acquisition (described in Note 5 of the Company's Form 10-K as of December 31, 2008). As of September 30, 2009, the Company has paid the Term Loan in full. The Loan Agreement also provides for a short-term revolving credit facility of \$6,000 (the "Revolving Facility"). The Revolving Facility is subject to a monthly interest rate equal to LIBOR plus 1%, and accrued interest is payable monthly. No amounts are outstanding on the Revolving Facility as of the date hereof. The Revolving Facility has a maturity date of May 31, 2010. Management believes that such facility will be renewed in the normal course of business.

NOTE 11 - EMPLOYEE BENEFIT PLAN

The Company currently provides postretirement benefits in the form of a retirement medical plan under a collective bargaining agreement covering eligible retired employees of its Verona, Missouri facility.

Net periodic benefit cost for such retirement medical plan for the nine months ended September 30, 2009 and September 30, 2008 was as follows:

	2009	2008
Service cost	\$ 24	\$ 21
Interest cost	32	30
Expected return on plan assets	--	--

Edgar Filing: BALCHEM CORP - Form 10-Q

Amortization of transition obligation	--	--
Amortization of prior service cost	(14)	(14)
Amortization of gain	(2)	(4)

Net periodic benefit cost	\$ 40	\$ 33

The amount recorded on the Company's balance sheet as of September 30, 2009 for this obligation is \$871. The plan is unfunded and approved claims are paid from Company funds. Historical cash payments made under such plan approximated \$50 per year.

NOTE 12 - COMMITMENTS AND CONTINGENCIES

As part of the June 30, 2005 acquisition of certain assets relating to the encapsulation, agglomeration and granulation business of Loders Croklaan USA, LLC, the Company entered into a lease agreement with Loders under which the Company leases a portion of Loders' Channahon, Illinois facility where it principally conducted the manufacturing portion of the acquired business and utilized certain warehouse space. The initial term of the lease commenced in February, 2006 and runs through September 30, 2010, subject to earlier termination.

In February 2002, the Company entered into a ten (10) year lease, which is cancelable in 2009, for approximately 20,000 square feet of office space. The office space is now serving as the Company's general offices and as a laboratory facility. The Company leases most of its vehicles, railcars and office equipment under non-cancelable operating leases, which primarily expire at various times through 2015. Rent expense charged to operations under such lease agreements for the nine months ended September 30, 2009 and 2008 aggregated approximately \$909 and \$867, respectively. Aggregate future minimum rental payments required under all non-cancelable operating leases at September 30, 2009 are as follows:

Year	

October 1, 2009 to December 31, 2009	\$ 280
2010	990
2011	705
2012	361
2013	183
2014	120
Thereafter	216

Total minimum lease payments	\$ 2,855

In 1982, the Company discovered and thereafter removed a number of buried drums containing unidentified waste material from the Company's site in Slate Hill, New York. The Company thereafter entered into a Consent Decree to evaluate the drum site with the New York Department of Environmental Conservation ("NYDEC") and performed a Remedial Investigation/Feasibility Study that was approved by NYDEC in February 1994. Based on NYDEC requirements, the Company cleaned the area and removed additional soil from the drum burial site, which was completed in 1996. The Company

continues to be involved in discussions with NYDEC to evaluate test results and

Edgar Filing: BALCHEM CORP - Form 10-Q

determine what, if any, additional actions will be required on the part of the Company to close out the remediation of this site. Additional actions, if any, would likely require the Company to continue monitoring the site. The cost of such monitoring has been less than \$5 per year for the period 2003 to date.

The Company's Verona, Missouri facility, while held by a prior owner, was designated by the EPA as a Superfund site and placed on the National Priorities List in 1983, because of dioxin contamination on portions of the site. Remediation conducted by the prior owner under the oversight of the EPA and the Missouri Department of Natural Resources ("MDNR") included removal of dioxin contaminated soil and equipment, capping of areas of residual contamination in four relatively small areas of the site separate from the manufacturing facilities, and the installation of wells to monitor groundwater and surface water contamination by organic chemicals. No ground water or surface water treatment was required. The Company believes that remediation of the site is complete. In 1998, the EPA certified the work on the contaminated soils to be complete. In February 2000, after the conclusion of two years of monitoring groundwater and surface water, the former owner submitted a draft third party risk assessment report to the EPA and MDNR recommending no further action. The prior owner is awaiting the response of the EPA and MDNR to the draft risk assessment.

While the Company must maintain the integrity of the capped areas in the remediation areas on the site, the prior owner is responsible for completion of any further Superfund remedy. The Company is indemnified by the sellers under its May 2001 asset purchase agreement covering its acquisition of the Verona, Missouri facility for potential liabilities associated with the Superfund site and one of the sellers, in turn, has the benefit of certain contractual indemnification by the prior owner that is implementing the above-described Superfund remedy.

From time to time, the Company is a party to various litigation, claims and assessments. Management believes that the ultimate outcome of such matters will not have a material effect on the Company's consolidated financial position, results of operations, or liquidity.

NOTE 13 - NEW ACCOUNTING PRONOUNCEMENTS

In August 2009, the FASB issued Accounting Standards Update ("ASU") No. 2009-5, "Measuring Liabilities at Fair Value" ("ASU 2009-05"). ASU 2009-05 amends ASC 820, "Fair Value Measurements and Disclosures." Specifically, ASU 2009-05 provides clarification that in circumstances in which a quoted price in an active market for the identical liability is not available, a reporting entity is required to measure fair value using one or more of the following methods: 1) a valuation technique that uses a) the quoted price of the identical liability when traded as an asset or b) quoted prices for similar liabilities or similar liabilities when traded as assets and/or 2) a valuation technique that is consistent with the principles of ASC 820 (e.g. an income approach or market approach). ASU 2009-05 also clarifies that when estimating the fair value of a liability, a reporting entity is not required to adjust to include inputs relating to the existence of transfer restrictions on that liability. ASU 2009-05 is effective for the Company on October 1, 2009. The Company does not expect the adoption of this guidance to be significant to its consolidated financial statements.

In June 2009, the FASB issued ASU 2009-01, "Topic 105-Generally Accepted Accounting Principles amendments based on Statement of Financial Accounting

Edgar Filing: BALCHEM CORP - Form 10-Q

Standards No. 168—"The FASB Accounting Standards Codification and the Hierarchy of Generally Accepted Accounting Principles" (incorporating former SFAS No. 168, "The FASB Accounting Standards Codification and the Hierarchy of Generally Accepted Accounting Principles - a Replacement of FASB Statement No. 162"), which establishes the FASB Accounting Standards Codification as the single source of authoritative U.S. generally accepted accounting principles recognized by FASB to be applied by nongovernmental entities. Rules and interpretive releases of the SEC under authority of federal securities laws are also sources of authoritative U.S. GAAP for SEC registrants. ASU 2009-01 and the Codification were effective for financial statements issued for interim and annual periods ending after September 15, 2009. The Codification supersedes all existing non-SEC accounting and reporting standards. All other nongrandfathered non-SEC accounting literature not included in the Codification is nonauthoritative. Following ASU 2009-01, FASB will not issue new standards in the form of Statements, FASB Staff Positions, or Emerging Issues Task Force Abstracts. Instead, FASB will issue Accounting Standards Updates, which will serve only to: (a) update the Codification; (b) provide background information about the guidance; and (c) provide the bases for conclusions on the change(s) in the Codification. Pursuant to the provisions of ASU 2009-01, the Company has updated references to GAAP in its financial statements issued for the period ended September 30, 2009. The adoption of ASU 2009-01 was not significant to the Company's consolidated financial statements.

In June 2009, the FASB issued SFAS No. 167, "Amendments to FASB Interpretation No. 46(R)" ("SFAS 167"). The amendments include: (1) the elimination of the exemption for qualifying special purpose entities, (2) a new approach for determining who should consolidate a variable-interest entity, and (3) changes to when it is necessary to reassess who should consolidate a variable-interest entity. SFAS 167 is effective for the first annual reporting period beginning after November 15, 2009 and for interim periods within that first annual reporting period. The Company does not expect the adoption of this statement to be significant to its consolidated financial statements.

In June 2009, the FASB issued SFAS No. 166, "Accounting for Transfers of Financial Assets, an amendment to SFAS No. 140" ("SFAS 166"). SFAS 166 eliminates the concept of a "qualifying special-purpose entity," changes the requirements for derecognizing financial assets, and requires additional disclosures in order to enhance information reported to users of financial statements by providing greater transparency about transfers of financial assets, including securitization transactions, and an entity's continuing involvement in and exposure to the risks related to transferred financial assets. SFAS 166 is effective for fiscal years beginning after November 15, 2009. The Company does not expect the adoption of this statement to be significant to its consolidated financial statements.

In May 2009, FASB issued ASC 855, "Subsequent Events" (incorporating former SFAS No. 165, "Subsequent Events"). ASC 855 establishes general standards of accounting for and disclosure of events that occur after the balance sheet date but before financial statements are issued or are available to be issued. Specifically, ASC 855 provides the period after the balance sheet date during which management of a reporting entity should evaluate events or transactions that may occur for potential recognition or disclosure in the financial statements; the circumstances under which an entity should recognize events or transactions occurring after the balance sheet date in its financial statements; and the

disclosures that an entity should make about events or transactions that occurred after the balance sheet date. ASC 855 was effective for interim or

Edgar Filing: BALCHEM CORP - Form 10-Q

annual financial periods ending after June 15, 2009, and is to be applied prospectively. The adoption of this guidance was not significant to the Company's consolidated financial statements. The Company has evaluated the financial statements for subsequent events through the date of the filing of this Form 10-Q on November 6, 2009.

In April 2009, FASB issued amended guidance (incorporating former FASB Staff Position ("FSP") FAS 141(R)-1, "Accounting for Assets Acquired and Liabilities Assumed in a Business Combination That Arise from Contingencies") incorporated into ASC 805, "Business Combinations" (incorporating former FASB Statement No. 141 (Revised December 2007), "Business Combinations"). This amended guidance requires assets acquired and liabilities assumed in a business combination that arise from contingencies to be recognized at fair value if fair value can be reasonably estimated. If fair value of such an asset or liability cannot be reasonably estimated, the asset or liability would generally be recognized in accordance with ASC 450, "Contingencies" (incorporating former SFAS No. 5, "Accounting for Contingencies"; and FASB Interpretation ("FIN") No. 14, "Reasonable Estimation of the Amount of a Loss."). Further, FASB decided to carry forward without significant revision the subsequent accounting guidance for assets and liabilities arising from contingencies as per SFAS No. 141, "Business Combinations." The amended guidance also eliminates the requirement to disclose an estimate of the range of outcomes of recognized contingencies at the acquisition date. For unrecognized contingencies, FASB decided to require that entities include only the disclosures required by ASC 450 and that those disclosures be included in the business combination footnote. This amended guidance also requires that contingent consideration arrangements of an acquiree assumed by the acquirer in a business combination be treated as contingent consideration of the acquirer and should be initially and subsequently measured at fair value in accordance with ASC 805. This amended guidance is effective for assets or liabilities arising from contingencies in business combinations for which the acquisition date is on or after January 1, 2009. The Company will apply this amended guidance prospectively to all business combinations subsequent to the effective date.

In April 2009, FASB issued ASC 820, "Fair Value Measurements and Disclosures" (incorporating former FSP FAS 157-4, "Determining Fair Value When the Volume and Level of Activity for the Asset or Liability Have Significantly Decreased and Identifying Transactions That Are Not Orderly"), and ASC 825, "Financial Instruments" (incorporating former FSP FASB 107-1 and Accounting Principles Board 28-1, "Interim Disclosures about Fair Value of Financial Instruments"). The guidance relates to fair value measurements and related disclosures. The FASB also issued ASC 320, "Investments-Debt and Equity Securities" (incorporating former FSP FAS 115-2 and FAS 124-2, "Recognition and Presentation of Other-Than-Temporary Impairments") relating to the accounting for impaired debt securities. This guidance is effective for interim and annual periods ending after June 15, 2009. This guidance is not significant to the Company's consolidated financial statements.

In April 2008, FASB issued ASC 350, "Intangibles-Goodwill and Other" (incorporating former FSP 142-3, "Determining the Useful Life of Intangible Assets"). ASC 350 amends the factors to be considered in determining the useful life of intangible assets. Its intent is to improve the consistency between the useful life of an intangible asset and

the period of expected cash flows used to measure its fair value. This guidance is effective for fiscal years beginning after December 15, 2008. The adoption of this guidance was not significant to the Company's consolidated financial statements.

Edgar Filing: BALCHEM CORP - Form 10-Q

In March 2008, FASB issued ASC 815, "Derivatives and Hedging" (incorporating former SFAS No. 161, "Disclosures about Derivative Instruments and Hedging Activities -- an amendment of FASB Statement No. 133"). ASC 815 requires enhanced disclosures regarding derivatives and hedging activities, including: (a) the manner in which an entity uses derivative instruments; (b) the manner in which derivative instruments and related hedged items are accounted for; and (c) the effect of derivative instruments and related hedged items on an entity's financial position, financial performance, and cash flows. ASC 815 is effective for financial statements issued for fiscal years and interim periods beginning after November 15, 2008. The adoption of this guidance was not significant to the Company's consolidated financial statements.

In December 2007, FASB issued ASC 805, "Business Combinations" (incorporating former SFAS No. 141 (revised 2007), "Business Combinations"). The purpose of issuing this new guidance was to replace current guidance in SFAS No. 141 to better represent the economic value of a business combination transaction. The changes to be effected with this new guidance from the current guidance include, but are not limited to: (1) acquisition costs will be recognized separately from the acquisition; (2) known contractual contingencies at the time of the acquisition will be considered part of the liabilities acquired measured at their fair value; all other contingencies will be part of the liabilities acquired measured at their fair value only if it is more likely than not that they meet the definition of a liability; (3) contingent consideration based on the outcome of future events will be recognized and measured at the time of the acquisition; (4) business combinations achieved in stages (step acquisitions) will need to recognize the identifiable assets and liabilities, as well as noncontrolling interests, in the acquiree, at the full amounts of their fair values; and (5) a bargain purchase (defined as a business combination in which the total acquisition-date fair value of the identifiable net assets acquired exceeds the fair value of the consideration transferred plus any noncontrolling interest in the acquiree) will require that excess to be recognized as a gain attributable to the acquirer. ASC 805 is effective for any business combinations that occur on or after January 1, 2009. The Company will apply ASC 805 prospectively to all business combinations subsequent to the effective date.

In December 2007, the FASB issued ASC 810, "Consolidation" (incorporating former SFAS No. 160, "Noncontrolling Interests in Consolidated Financial Statements -- an amendment of ARB No. 51"). The guidance was issued partly to improve the relevance, comparability, and transparency of financial information provided to investors by requiring all entities to report noncontrolling (minority) interests in subsidiaries in the same way, that is, as equity in the consolidated financial statements. Moreover, ASC 810 eliminates the diversity that currently exists in accounting for transactions between an entity and noncontrolling interests by requiring they be treated as equity transactions. ASC 810 was effective January 1, 2009. The adoption of this guidance was not significant to the Company's consolidated financial statements.

In September 2006, FASB issued ASC 820, "Fair Value Measurements and Disclosures" (incorporating former SFAS No. 157, "Fair Value Measurements"). ASC 820 defines fair value, establishes a framework for measuring fair value in accordance with generally accepted accounting principles and expands disclosures about fair value measurements.

The Company adopted the provisions of this standard for its financial assets and liabilities as of January 1, 2008 and it did not have a material impact on its financial condition or results of operations. As permitted by additional guidance (issued formerly as FSP No. FAS 157-2, "Effective Date of FASB

Edgar Filing: BALCHEM CORP - Form 10-Q

Statement No. 157"), the Company elected to defer the adoption of ASC 820 for all nonfinancial assets and nonfinancial liabilities, except those that are recognized or disclosed at fair value in the financial statements on a recurring basis, until January 1, 2009. Effective January 1, 2009, the Company adopted the provision for nonfinancial assets and liabilities that are not required or permitted to be measured at fair value on a recurring basis, which include those measured at fair value in impairment testing and those initially measured at fair value in a business combination. The provisions of ASC 820 related to these items did not have a significant impact on the Company's consolidated financial statements. Additional guidance (issued formerly as FSP No. 157-3, "Determining the Fair Value of a Financial Asset When the Market for That Asset is Not Active") clarifies the application of ASC 820 in a market that is not active and provides an example of key considerations in determining the fair value of a financial asset when the market for that asset is not active. This additional guidance was effective on October 10, 2008, including prior periods for which financial statements have not been issued. Revisions resulting from a change in the valuation technique or its application should be accounted for as a change in accounting estimate following the guidance in ASC 250, "Accounting Changes and Error Corrections" (incorporating former SFAS No. 154, "Accounting Changes and Error Corrections"). The Company adopted the additional guidance on October 10, 2008 and it did not have a material effect on its consolidated financial statements.

20

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations (All dollar amounts in thousands)

This Report contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, which reflect our expectation or belief concerning future events that involve risks and uncertainties. Our actions and performance could differ materially from what is contemplated by the forward-looking statements contained in this Report. Factors that might cause differences from the forward-looking statements include those referred to or identified in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2008 and other factors that may be identified elsewhere in this Report. Reference should be made to such factors and all forward-looking statements are qualified in their entirety by the above cautionary statements.

FASB Codification

We follow accounting standards set by the Financial Accounting Standards Board, commonly referred to as the "FASB." The FASB sets U.S. generally accepted accounting principles ("U.S. GAAP" or "GAAP") that we follow to ensure we consistently report our financial condition, results of operations, and cash flows. Over the years, the FASB and other designated GAAP-setting bodies, have issued standards in the form of FASB Statements, Interpretations, FASB Staff Positions, EITF consensuses, AICPA Statements of Position, etc.

The FASB recognized the complexity of its standard-setting process and embarked on a revised process in 2004 that culminated in the release on July 1, 2009, of the FASB Accounting Standards Codification, sometimes referred to as the "Codification" or "ASC". The Codification does not change how the Company accounts for its transactions or the nature of related disclosures made. However, when referring to guidance issued by the FASB, the Company refers to topics in the ASC rather than Statements, etc. The above change was made effective by the FASB for periods ending on or after September 15, 2009. We have updated references to GAAP in this Quarterly Report on Form 10-Q to reflect the guidance in the Codification.

Edgar Filing: BALCHEM CORP - Form 10-Q

Overview

We develop, manufacture, distribute and market specialty performance ingredients and products for the food, nutritional, pharmaceutical, animal health and medical device sterilization industries. Our reportable segments are strategic businesses that offer products and services to different markets. We presently have three reportable segments: Specialty Products; Food, Pharma & Nutrition; and Animal Nutrition & Health.

Specialty Products

Our Specialty Products segment operates in industry as ARC Specialty Products.

Ethylene oxide, at the 100% level, is sold as a sterilant gas, primarily for use in the health care industry. It is used to sterilize a wide range of medical devices because of its versatility and effectiveness in treating hard or soft surfaces, composites, metals, tubing and different types of plastics without negatively impacting the performance of the device being sterilized. Our 100% ethylene oxide product is distributed in uniquely designed,

21

recyclable, double-walled, stainless steel drums to assure compliance with safety, quality and environmental standards as outlined by the U.S. Environmental Protection Agency (the "EPA") and the U.S. Department of Transportation. Our inventory of these specially built drums, along with our two filling facilities, represents a significant capital investment. Contract sterilizers, medical device manufacturers, and medical gas distributors are our principal customers for this product. In addition, we also sell single use canisters with 100% ethylene oxide for use in medical device sterilization. As a fumigant, ethylene oxide blends are highly effective in killing bacteria, fungi, and insects in spices and other seasoning materials.

We also sell propylene oxide principally to customers seeking smaller (as opposed to bulk) quantities and whose requirements include timely delivery and safe handling. Propylene oxide uses can include fumigation in spice treatment, various chemical synthesis applications, to make paints more durable, and for manufacturing specialty starches and textile coatings.

Food, Pharma & Nutrition

The Food, Pharma & Nutrition ("FP&N") segment provides microencapsulation, granulation and agglomeration solutions to a variety of applications in food, pharmaceutical and nutritional ingredients to enhance performance of nutritional fortification, processing, mixing, and packaging applications and shelf-life. Major product applications are baked goods, refrigerated and frozen dough systems, processed meats, seasoning blends, confections, and nutritional supplements. We also market human grade choline nutrient products through this segment for wellness applications. Choline is recognized to play a key role in the development and structural integrity of brain cell membranes in infants, processing dietary fat, reproductive development and neural functions, such as memory and muscle function. The FP&N portfolio also includes granulated calcium carbonate products, primarily used in, or in conjunction with, novel over-the-counter and prescription pharmaceuticals for the treatment of osteoporosis, gastric disorders and calcium deficiencies in the United States.

Edgar Filing: BALCHEM CORP - Form 10-Q

Animal Nutrition & Health

Our Animal Nutrition & Health ("AN&H") segment provides the animal nutrition market with nutritional products derived from our encapsulation and chelation technologies in addition to basic choline chloride. Commercial sales of REASHURE(R) Choline, an encapsulated choline product, NITROSHURE(TM), an encapsulated urea supplement, and NIASHURE(TM), our microencapsulated niacin product for dairy cows, boosts health and milk production in transition and lactating dairy cows, delivering nutrient supplements that survive the rumen and are biologically available, providing required nutritional levels. We also market chelated mineral supplements for use in animal feed throughout the world, as our proprietary chelation technology provides enhanced nutrient absorption for various species of production and companion animals. In October 2008, we introduced the first proven rumen-protected lysine for use in dairy rations, AMINOSHURE(TM)-L, which gives nutritionists and dairy producers a precise and consistent source of rumen-protected lysine. AN&H also manufactures and supplies basic choline chloride, an essential nutrient for animal health, predominantly to the poultry and swine industries. Choline, which is manufactured and sold in both dry and aqueous forms, plays a vital role in the metabolism of fat. Choline deficiency can result in reduced growth and perosis in poultry; fatty liver, kidney necrosis and general poor health

22

condition in swine. Certain derivatives of choline chloride are also manufactured and sold into industrial applications. The AN&H segment also includes the manufacture and sale of methylamines. Methylamines are a primary building block for the manufacture of choline products and are also used in a wide range of industrial applications.

We sell products for all three segments through our own sales force, independent distributors, and sales agents.

The following tables summarize consolidated net sales by segment and business segment earnings from operations for the three and nine months ended September 30, 2009 and September 30, 2008:

Business Segment Net Sales:

	Three Months Ended September 30,		Nine Months End September	
	2009	2008	2009	
Specialty Products	\$ 9,119	\$ 9,298	\$ 27,006	\$
Food, Pharma & Nutrition	8,639	9,362	26,034	
Animal Nutrition & Health	36,534	39,575	107,214	
Total	\$54,292	\$58,235	\$160,254	\$

Business Segment Earnings From Operations:

Edgar Filing: BALCHEM CORP - Form 10-Q

	Three Months Ended		Nine Months Ended	
	September 30,		September 30,	
	2009	2008	2009	2008
Specialty Products	\$ 3,686	\$3,391	\$10,822	\$ 8,709
Food, Pharma & Nutrition	1,342	1,565	3,584	4,763
Animal Nutrition & Health	5,275	2,270	15,492	8,398
Total	\$10,303	\$7,226	29,898	21,870

23

RESULTS OF OPERATIONS

Three months ended September 30, 2009 compared to three months ended September 30, 2008.

Net Sales

Net sales for the three months ended September 30, 2009 were \$54,292, as compared with \$58,235 for the three months ended September 30, 2008, a decrease of \$3,943 or 6.8%. Net sales for the Specialty Products segment were \$9,119 for the three months ended September 30, 2009, as compared with \$9,298 for the three months ended September 30, 2008, a decrease of \$179 or 1.9%. This decrease in sales was principally a result of a decline in sales of propylene oxide in the quarter, a result of slowness and order timing of industrial end use markets. Net sales for the Food, Pharma & Nutrition segment were \$8,639 for the three months ended September 30, 2009 compared with \$9,362 for the three months ended September 30, 2008, a decrease of \$723 or 7.7%. This result was driven principally by aggressive inventory management by customers along with lower sales into the international food market, and volume declines in the human-grade choline and calcium products for the supplement market, which has been negatively impacted by the worldwide economic downturn. These declines were partially offset by a favorable product mix sold in the domestic food market, including the growth of choline into new food applications as well as growth in the tortilla and preservation markets. Also offsetting the declines were higher sales of Vitashure(R) products for nutritional enhancement. Net sales of \$36,534 were realized for the three months ended September 30, 2009 for the Animal Nutrition & Health segment, as compared with \$39,575 for the prior year comparable quarter, a decrease of \$3,041 or 7.7%. Feed and industrial grade choline product sales and derivatives decreased 9.3% or \$3,091 over the prior year quarter, as we realized lower export sales from our North American choline plants, largely due to the stronger U.S. dollar in 2009 versus 2008. This currency change also negatively impacted our translated sales of Euro denominated choline sold from our Italian operation. Sales were also lower due to reduced pricing linked to the decline in raw material costs. Sales of industrial derivatives (both choline and methylamines) were impacted by softness in the industrial sector, principally caused by the general economic downturn.

Operating Expenses

Operating expenses for the three months ended September 30, 2009 were \$6,096, as compared to \$5,486 for the three months ended September 30, 2008, an increase of

Edgar Filing: BALCHEM CORP - Form 10-Q

\$610 or 11.1%. This increase was due primarily to increased payroll expenses. Operating expenses were 11.2% of sales or 1.8 percentage points more than the operating expenses as a percent of sales incurred in last year's comparable quarter. During the three months ended September 30, 2009 and 2008, the Company spent \$740 and \$681 respectively, on research and development programs, substantially all of which pertained to the Company's Food, Pharma & Nutrition and Animal Nutrition & Health segments.

Business Segment Earnings From Operations

Earnings from operations for the three months ended September 30, 2009 increased to \$10,303 compared to \$7,226 for the three months ended September 30, 2008, an increase

24

of \$3,077 or 42.6%. This increase was primarily driven by cost reductions of certain petro-chemical raw materials over the prior year comparable quarter, a favorable product mix, and plant and logistics efficiencies. Earnings from operations as a percentage of sales ("operating margin") for the three months ended September 30, 2009 increased to 19.0% compared to 12.4% for the three months ended September 30, 2008, principally a result of the aforementioned product mix, cost reductions of certain petro-chemical raw materials, and plant and logistics efficiencies. Earnings from operations for the Specialty Products segment were \$3,686, an increase of \$295 or 8.7%, primarily due to reductions in the cost of certain petro-chemical raw materials and increases in average selling prices. Earnings from operations for Food, Pharma & Nutrition were \$1,342, a decrease of \$223 or 14.2%, due largely to the aforementioned aggressive inventory management by customers, lower sales into the international food market, and volume declines in the human-grade choline and calcium products for the supplement market. Earnings from operations for Animal Nutrition & Health increased by \$3,005 to \$5,275, a 132.4% increase from the prior comparable quarter, resulting principally from reductions in the cost of certain petro-chemical raw materials and improved production/supply chain efficiencies in both the U.S. and Europe.

Other Expenses (Income)

Interest income for the three months ended September 30, 2009 totaled \$8 as compared to \$17 for the three months ended September 30, 2008. Interest expense was \$27 for the three months ended September 30, 2009 compared to \$222 for the three months ended September 30, 2008. This decrease is primarily attributable to the decrease in average current and long-term debt resulting from both normal recurring principal payments as well as accelerated payments of the Term Loan (as defined below in the Financing Activities section of Liquidity and Capital Resources). Other income of \$39 for the three months ended September 30, 2009 is primarily the result of favorable fluctuations in foreign currency exchange rates between the U.S. dollar (the reporting currency) and functional foreign currencies.

Income Tax Expense

The Company's effective tax rate for the three months ended September 30, 2009 and 2008 was 33.6% and 30.9% respectively. This increase in the effective tax rate is primarily attributable to a change in the income proportion towards jurisdictions with higher tax rates.

Edgar Filing: BALCHEM CORP - Form 10-Q

Net Earnings

Primarily as a result of the above-noted cost reductions of certain petro-chemical raw materials, favorable product mix, and plant and logistics efficiencies, net earnings were \$6,852 for the three months ended September 30, 2009, as compared with \$4,793 for the three months ended September 30, 2008, an increase of 43.0%.

25

Nine months ended September 30, 2009 compared to Nine months ended September 30, 2008.

Net Sales

Net sales for the nine months ended September 30, 2009 were \$160,254, as compared with \$177,997 for the nine months ended September 30, 2008, a decrease of \$17,743 or 10.0%. Net sales for the Specialty Products segment were \$27,006 for the nine months ended September 30, 2009, as compared with \$26,564 for the nine months ended September 30, 2008, an increase of \$442 or 1.7%. This increase in sales was derived principally from increases in the average selling prices of certain ethylene oxide products for medical device sterilization. Net sales for the Food, Pharma & Nutrition segment were \$26,034 for the nine months ended September 30, 2009 compared with \$28,122 for the nine months ended September 30, 2008, a decrease of \$2,088 or 7.4%. This result was driven principally by aggressive inventory management by customers along with volume declines in the human-grade choline and calcium products for the supplement market, which has been negatively impacted by the worldwide economic downturn. These declines were partially offset by a favorable product mix sold in the domestic food market, including the growth of choline into new food applications as well as growth in the bakery, tortilla and preservation markets. Also offsetting the declines was increased sales of Vitashure(R) products for nutritional enhancement. Net sales of \$107,214 were realized for the nine months ended September 30, 2009 for the Animal Nutrition & Health segment, as compared with \$123,311 for the prior year comparable period, a decrease of \$16,097 or 13.1%. Feed and industrial grade choline product sales and derivatives decreased 14.7% or \$15,442 over the prior year period, principally from well-publicized softness in the U.S. poultry and swine markets. There were also lower export sales from our North American choline plants, largely due to the stronger U.S. dollar in 2009 versus 2008 and international political factors affecting poultry exports. This U.S. volume decline was partially offset by increased volumes of choline products sourced from our Italian operation into the European and international poultry markets. This geographic mix lowered consolidated feed grade prices in the period, as did lower pricing linked to the decline in raw material costs. Sales of industrial derivatives (both choline and methylamines) were impacted by softness in the industrial sector, principally caused by the general economic downturn. Sales of our specialty animal nutrition and health products, targeted for ruminant production animals and companion animals, decreased 3.6% or \$655 from the prior year comparable period primarily due to weak dairy economics which resulted in lower demand for our products. Partially offsetting this decrease were new sales generated from AminoShure(TM)-L, the Company's rumen protected lysine product.

Operating Expenses

Operating expenses for the nine months ended September 30, 2009 were \$20,103 as compared to \$17,276 for the nine months ended September 30, 2008, an increase of \$2,827 or 16.4%. This increase was due primarily to increased payroll expenses

Edgar Filing: BALCHEM CORP - Form 10-Q

along with an increase to some accounts receivable reserves for international accounts. Operating expenses were 12.5% of sales or 2.8 percentage points more than the operating

26

expenses as a percent of sales incurred in last year's comparable period. During the nine months ended September 30, 2009 and 2008, the Company spent \$2,428 and \$2,164 respectively, on research and development programs, substantially all of which pertained to the Company's Food, Pharma & Nutrition and Animal Nutrition & Health segments.

Business Segment Earnings From Operations

Earnings from operations for the nine months ended September 30, 2009 increased to \$29,898 compared to \$21,870 for the nine months ended September 30, 2008, an increase of \$8,028 or 36.7%. This increase was primarily driven by cost reductions of certain petro-chemical raw materials over the prior year comparable period, a favorable product mix, and plant and logistics efficiencies. Earnings from operations as a percentage of sales ("operating margin") for the nine months ended September 30, 2009 increased to 18.7% compared to 12.3% for the nine months ended September 30, 2008, principally a result of the aforementioned cost reductions of certain petro-chemical raw materials over the prior year comparable period, a favorable product mix, and plant and logistics efficiencies. Earnings from operations for the Specialty Products segment were \$10,822, an increase of \$2,113 or 24.3%, primarily due to reductions in the cost of certain petro-chemical raw materials and increases in average selling prices. Earnings from operations for Food, Pharma & Nutrition were \$3,584, a decrease of \$1,179 or 24.8%, due largely to the aforementioned aggressive inventory management by customers and volume declines in the human-grade choline and calcium products for the supplement market. Earnings from operations for Animal Nutrition & Health increased by \$7,094 to \$15,492, an 84.5% increase from the prior year, resulting principally from reductions in the cost of certain petro-chemical raw materials and improved production/supply chain efficiencies in both the U.S. and Europe.

Other Expenses (Income)

Interest income for the nine months ended September 30, 2009 totaled \$38 as compared to \$66 for the nine months ended September 30, 2008. Interest expense was \$142 for the nine months ended September 30, 2009 compared to \$792 for the nine months ended September 30, 2008. This decrease is primarily attributable to the decrease in average current and long-term debt resulting from both normal recurring principal payments as well as accelerated payments of the Term Loan (as defined below in the Financing Activities section of Liquidity and Capital Resources). Other expense of \$2 for the nine months ended September 30, 2009 is primarily the result of unfavorable fluctuations in foreign currency exchange rates between the U.S. dollar (the reporting currency) and functional foreign currencies.

Income Tax Expense

The Company's effective tax rate for the nine months ended September 30, 2009 and 2008 was 33.5% and 33.0% respectively. This increase in the effective tax rate is primarily attributable to a change in the income proportion towards jurisdictions with higher tax rates.

Net Earnings

Primarily as a result of the above-noted cost reductions of certain petro-chemical raw materials, the favorable product mix, and plant and logistics efficiencies, net earnings were \$19,819 for the nine months ended September 30, 2009, as compared with \$14,158 for the nine months ended September 30, 2008, an increase of 40.0%.

FINANCIAL CONDITION

LIQUIDITY AND CAPITAL RESOURCES

Contractual Obligations

The Company's contractual obligations and commitments principally include obligations associated with future minimum non-cancelable operating lease obligations (including for the headquarters office space entered into in 2002), long-term debt obligations and purchase obligations principally related to open purchase orders for inventory not yet received or recorded on our balance sheet.

The Company knows of no current or pending demands on, or commitments for, its liquid assets that will materially affect its liquidity.

During the nine months ended September 30, 2009, there were no material changes outside the ordinary course of business in the specified contractual obligations set forth in our Annual Report on Form 10-K for the year ended December 31, 2008. The Company expects its operations to continue generating sufficient cash flow to fund working capital requirements and necessary capital investments. The Company is actively pursuing additional acquisition candidates. The Company could seek additional bank loans or access to financial markets to fund such acquisitions, its operations, working capital, necessary capital investments or other cash requirements should it deem it necessary to do so.

Cash

Cash and cash equivalents increased to \$38,778 at September 30, 2009 from \$3,422 at December 31, 2008 primarily resulting from the information detailed below. Working capital amounted to \$52,930 at September 30, 2009 as compared to \$29,566 at December 31, 2008, an increase of \$23,364.

Operating Activities

Cash flows from operating activities provided \$39,065 for the nine months ended September 30, 2009 compared to \$17,229 for the nine months ended September 30, 2008. The increase in cash flows from operating activities was primarily due to an increase in net earnings, lower accounts receivable, a decrease in inventories and prepaid expenses, and increased accounts payable and accrued expenses.

Edgar Filing: BALCHEM CORP - Form 10-Q

Investing Activities

Capital expenditures were \$2,141 for the nine months ended September 30, 2009 compared to \$4,128 for the nine months ended September 30, 2008.

Financing Activities

The Company has an approved stock repurchase program. The total authorization under this program is 2,508,692 shares. Since the inception of the program, a total of 1,307,867 shares have been purchased, none of which remained in treasury at September 30, 2009 or 2008. During the nine months ended September 30, 2009, no additional shares have been purchased. The Company intends to acquire shares from time to time at prevailing market prices if and to the extent it deems it advisable to do so based on its assessment of corporate cash flow, market conditions and other factors.

On April 30, 2007, the Company, and its principal bank entered into a Loan Agreement (the "European Loan Agreement") providing for an unsecured term loan of (euro)7,500, translated to \$10,943 as of September 30, 2009 (the "European Term Loan"), the proceeds of which were used to fund the 2007 Akzo Nobel Acquisition (described in Note 5 of the Company's Form 10-K as of December 31, 2008) and initial working capital requirements. The European Term Loan is payable in equal monthly installments of principal, each equal to 1/84th of the principal of the European Term Loan, together with accrued interest, with remaining principal and interest payable at maturity. The European Term Loan has a maturity date of May 1, 2010 and is subject to a monthly interest rate equal to EURIBOR plus 1%. At September 30, 2009, this interest rate was 1.49%. At September 30, 2009, the European Term Loan had an outstanding balance of (euro)5,000, translated to \$7,295. The European Loan Agreement also provides for a short-term revolving credit facility of (euro)3,000, translated to \$4,377 as of September 30, 2009 (the "European Revolving Facility"). The European Revolving Facility has been renewed for a period of one year as of May 1, 2009. The current European Revolving Facility is subject to an amended monthly interest rate equal to EURIBOR plus 1.45%, and accrued interest is payable monthly. No amounts are outstanding on the European Revolving Facility as of the date hereof. Management believes that such facility will be renewed in the normal course of business.

On March 16, 2007, the Company and its principal bank entered into a Loan Agreement (the "Loan Agreement") providing for an unsecured term loan of \$29,000 (the "Term Loan"), the proceeds of which were used to fund the 2007 Chinook Acquisition (described in Note 5 of the Company's Form 10-K as of December 31, 2008). As of September 30, 2009, the Company has paid the Term Loan in full. The Loan Agreement also provides for a short-term revolving credit facility of \$6,000 (the "Revolving Facility"). The Revolving Facility is subject to a monthly interest rate equal to LIBOR plus 1%, and accrued interest is payable monthly. No amounts are outstanding on the Revolving Facility as of the date hereof. The Revolving Facility has a maturity date of May 31, 2010. Management believes that such facility will be renewed in the normal course of business.

29

Proceeds from stock options exercised totaled \$2,712 and \$1,000 for the nine months ended September 30, 2009 and 2008, respectively. Dividend payments were \$2,008 and \$1,975 for the nine months ended September 30, 2009 and 2008, respectively.

Edgar Filing: BALCHEM CORP - Form 10-Q

Other Matters Impacting Liquidity

The Company currently provides postretirement benefits in the form of a retirement medical plan under a collective bargaining agreement covering eligible retired employees of its Verona, Missouri facility. The amount recorded on the Company's balance sheet as of September 30, 2009 for this obligation is \$871. The postretirement plan is not funded. Historical cash payments made under such plan have approximated \$50 per year.

Critical Accounting Policies

There were no changes to the Company's Critical Accounting Policies, as described in its December 31, 2008 Annual Report on Form 10-K, during the nine months ended September 30, 2009.

Related Party Transactions

The Company was not engaged in related party transactions during the nine months ended September 30, 2009.

30

Item 3. Quantitative and Qualitative Disclosures about Market Risk

Cash and cash equivalents are invested primarily in money market accounts. The money market funds in which the Company invests are participants in the United States Treasury Department's Temporary Guarantee Program for Money Market Funds. This program provides coverage for amounts held in money market funds as of the close of business on September 19, 2008. The Company has no derivative financial instruments or derivative commodity instruments, nor does the Company have any financial instruments entered into for trading or hedging purposes. As of September 30, 2009, the Company's borrowings were under a bank term loan bearing interest at EURIBOR plus 1.00% and a revolving line of credit bearing interest at EURIBOR plus 1.45%. A 100 basis point increase or decrease in interest rates, applied to the Company's borrowings at September 30, 2009, would result in an increase or decrease in annual interest expense and a corresponding reduction or increase in cash flow of approximately \$73. The Company is exposed to market risks for changes in foreign currency rates and has exposure to commodity price risks, including prices of our primary raw materials. Our objective is to seek a reduction in the potential negative earnings impact of changes in foreign exchange rates and raw material pricing arising in our business activities. The Company manages these financial exposures, where possible, through pricing and operational means. Our practices may change as economic conditions change.

31

Item 4. Controls and Procedures

(a) Evaluation of Disclosure Controls and Procedures

Pursuant to the requirements of the Sarbanes-Oxley Act of 2002, the Company's management, under the supervision and with the participation of the Company's Chief Executive Officer and Chief Financial Officer, has evaluated, as of the end of the period covered by this Quarterly Report on Form 10-Q, the effectiveness of the Company's disclosure controls and

Edgar Filing: BALCHEM CORP - Form 10-Q

procedures (including its internal controls and procedures.) Based upon management's evaluation, the Chief Executive Officer and the Chief Financial Officer have concluded that, as of the end of such period, the Company's disclosure controls and procedures were effective in identifying the information required to be disclosed in the Company's periodic reports filed with the Securities and Exchange Commission ("SEC"), including this Quarterly Report on Form 10-Q, and ensuring that such information is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms.

(b) Changes in Internal Controls

During the most recent fiscal quarter, there has been no significant change in the Company's internal control over financial reporting that has materially affected, or is reasonably likely to materially affect, the Company's internal control over financial reporting.

32

Part II. Other Information

Item 1A. Risk Factors

There have been no material changes in the Risk Factors identified in the Company's Annual Report on Form 10-K for the year ended December 31, 2008.

Item 4. Submission of Matters to a Vote of Security Holders.

None.

Item 6.

Exhibits

Exhibit 31.1	Certification of Chief Executive Officer pursuant to Rule 13a-14(a).
Exhibit 31.2	Certification of Chief Financial Officer pursuant to Rule 13a-14(a).
Exhibit 32.1	Certification of Chief Executive Officer pursuant to Rule 13a-14(b) and Section 1350 of Chapter 63 of Title 18 of the United States Code.
Exhibit 32.2	Certification of Chief Financial Officer pursuant to Rule 13a-14(b) and Section 1350 of Chapter 63 of Title 18 of the United States Code.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

BALCHEM CORPORATION

By: /s/ Dino A. Rossi

Edgar Filing: BALCHEM CORP - Form 10-Q

Dino A. Rossi, Chairman, President and
Chief Executive Officer

Date: November 6, 2009

33

Exhibit Index

Exhibit No. -----	Description -----
Exhibit 31.1	Certification of Chief Executive Officer pursuant to Rule 13a-14(a).
Exhibit 31.2	Certification of Chief Financial Officer pursuant to Rule 13a-14(a).
Exhibit 32.1	Certification of Chief Executive Officer pursuant to Rule 13a-14(b) and Section 1350 of Chapter 63 of Title 18 of the United States Code.
Exhibit 32.2	Certification of Chief Financial Officer pursuant to Rule 13a-14(b) and Section 1350 of Chapter 63 of Title 18 of the United States Code.

34